• CD40 and STING Competition Drives B Cell Activation in ESCC

  2026-04-25

  This study reveals how CD40 and STING competitively bind TRAF2 to regulate IRF4-mediated B cell activation within tertiary lymphoid structures in esophageal squamous cell carcinoma (ESCC). These findings clarify key molecular mechanisms underlying adaptive antitumor immunity and suggest new avenues for biomarker and therapeutic development.

• Poria cocos Polysaccharides Mitigate ALD via NRF2/Ferroptosi

  2026-04-24

  This study uncovers how Poria cocos polysaccharides (PCP) ameliorate alcoholic liver disease (ALD) by modulating the NRF2 signaling pathway and suppressing ferroptosis. The findings highlight PCP's potential to regulate oxidative stress and inflammatory responses in ALD models, opening new avenues for targeted liver disease intervention.

• Ibrexafungerp vs. Caspofungin: Insights Against Resistant C.

  2026-04-24

  Wiederhold et al. investigate ibrexafungerp's in vitro and in vivo efficacy against fluconazole-resistant Candida auris, utilizing delayed therapy initiation in an experimental candidiasis model. The study benchmarks triterpenoid and lipopeptide antifungal drugs for activity against multidrug-resistant Candida, directly informing protocol optimization and resistance management strategies.

• Methionine γ-Lyase Essential for Biofilm in Synechococcus el

  2026-04-23

  This study demonstrates that a methionine γ-lyase homolog is indispensable for biofilm formation in the cyanobacterium Synechococcus elongatus. Through targeted genetic and protein-interaction experiments, the authors reveal that biofilm development requires specific enzymatic activity downstream of known biofilm gene induction, advancing our mechanistic understanding of cyanobacterial biofilm regulation.

• Affinity-Purified Goat Anti-Rabbit IgG (H+L): Workflow Maste

  2026-04-23

  Unlock next-generation sensitivity and reproducibility in immunoassays with the Affinity-Purified Goat Anti-Rabbit IgG (H+L), Horseradish Peroxidase Conjugated Secondary Antibody. This solution streamlines Western blot, ELISA, and IHC workflows, while minimizing troubleshooting cycles for complex translational research.

• Angiotensin III: Applied Protocols for Cardiovascular Resear

  2026-04-22

  Angiotensin III (human, mouse) unlocks high-fidelity RAAS signaling studies, serving as an optimal ligand for dissecting aldosterone secretion and pressor mechanisms. This guide delivers actionable protocols, troubleshooting strategies, and workflow enhancements to maximize reproducibility and interpretability in cardiovascular and neuroendocrine assays.

• PYR-41: Inhibitor of Ubiquitin-Activating Enzyme E1 for Path

  2026-04-22

  PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1, empowers researchers to dissect ubiquitin-proteasome system dynamics, modulate NF-κB signaling, and model inflammatory responses with quantified precision. Its performance in both cell-based and in vivo workflows—backed by robust benchmark data—makes it indispensable for protein degradation and inflammation research.

• A 83-01 (ALK-5 Inhibitor): Transforming Organoid Stemness Co

  2026-04-21

  Explore the specialized role of A 83-01 as a potent ALK-5 inhibitor in unlocking balanced self-renewal and differentiation in human organoid models. This article delivers a deeper mechanistic analysis and practical assay guidance beyond conventional TGF-β signaling studies.

• 5-HT3 Antagonists Inhibit Renal OCT2 and MATE1: In Vitro Ins

  2026-04-21

  This study elucidates how antiemetic 5-HT3 receptor antagonists, including tropisetron, inhibit renal organic cation transporters OCT2 and MATE1 in vitro. The findings highlight potential drug–drug interactions relevant to kidney drug handling and underscore the importance of transporter profiling in neuroscience and pharmacology research.

• MLN4924 HCl Salt: Optimizing NEDD8-Activating Enzyme Inhibit

  2026-04-20

  MLN4924 HCl salt empowers researchers to interrogate neddylation pathway inhibition with precision, unlocking new investigative angles in protein degradation, cell cycle arrest, and viral pathogenesis. APExBIO’s high-purity formulation ensures reproducibility in advanced cancer biology and antiviral workflows.

• Protoporphyrin IX: Optimizing Photodynamic Compound Workflow

  2026-04-20

  Protoporphyrin IX stands at the crossroads of heme biosynthesis and advanced photodynamic applications. This guide details robust experimental workflows and troubleshooting insights, empowering researchers to maximize reproducibility and sensitivity in cancer modeling and ferroptosis research with APExBIO’s high-purity compound.

• E-64d: Optimizing Cysteine Protease Inhibition in Cell Death

  2026-04-19

  E-64d stands out as a robust, membrane-permeable cysteine protease inhibitor, enabling precise dissection of calpain and cathepsin roles in apoptosis, platelet activation, and neuroprotection. This guide delivers actionable workflows, troubleshooting tactics, and insights from recent breakthroughs to maximize assay reproducibility and interpret complex regulated cell death pathways.

• Targeted mRNA Nanoparticles Restore BBB After Ischemic Strok

  2026-04-18

  This study introduces a targeted mRNA nanoparticle system that delivers interleukin-10 (IL-10) mRNA to promote M2 microglia polarization in the ischemic brain, resulting in improved blood-brain barrier (BBB) integrity and reduced neuroinflammation after stroke. The findings highlight a feedback-driven therapeutic strategy that extends the post-stroke intervention window, offering new directions for mRNA-based neuroprotection.

• PR-619: Deubiquitylating Enzymes Inhibitor for Pathway Resea

  2026-04-17

  PR-619 stands out as a broad-spectrum, cell-permeable deubiquitylating enzymes inhibitor, facilitating precise manipulation of the ubiquitination pathway in cancer and neurodegeneration models. Its reversible, non-proteasomal mechanism enables researchers to dissect DUB-dependent processes with clarity, offering robust performance in autophagy and cytotoxicity assays.

• PR-619: Deubiquitylating Enzymes Inhibitor for Assay Precisi

  2026-04-16

  Leverage the broad-spectrum, reversible inhibition of PR-619 to dissect the ubiquitination pathway in cancer, autophagy, and neurodegenerative research. This guide delivers workflow optimization, protocol parameters, and troubleshooting strategies to ensure robust, reproducible results—grounded in both literature and practical lab experience.

16512 records 1/1101 page Next 12345 下5页 Last page